I get great questions from readers of The Niche including, “Are there multiple ways to get stem cells?” The answer is “yes.” Why is this important? The different sources of stem cells can impact both their use in basic research and their potential clinically. My goal in today’s post is to give an overview of […]
Digging into the multiple ways to get stem cells Read More »
How promising is the idea of stem cells for MS? I have been working slowly as time permits on a piece more specifically about hematopoietic stem cell transplantation (HSCT) for MS. Two new pieces caught my eye on this topic so I’ll start with those. Stem cells for MS NurOwn Found Safe, Shows Promise in
Weekly reads: stem cells for MS, blood origins, iPSCs Read More »
When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are
ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »
Cloning is one of those topics that both fascinates and kind of scares people, especially the idea of duplicating people. I regularly cover the topic here on The Niche because stem cell technologies are involved. Also, one form of the process sometimes called “therapeutic cloning” involves embryonic stem cells. Duplicating mammals has now long been
Weekly reads: freeze-dried cloning, FDA signals, stem cell escapees Read More »
A few people in the stem cell field keep arguing that adult pluripotent stem cells exist, including so-called “very small embryonic-like stem cells” or VSEL stem cells. These days the supposed cells are called VSELs or V-cells too. Only a handful of researchers have ever been able to report finding and studying these cells. Others
Fact-checking VSEL stem cells & VSEL treatment Read More »
Some people consider the brain to be equivalent to a living computer and in that sense it’s too bad that computers don’t have the equal of neural stem cells to help them fix themselves. Is the internet one big neural network-like web? There was a quake in the stem cell internet as CIRM’s main website
Weekly reads: neural stem cells, CRISPR brain, Vertex, cytoplasm surprise Read More »
Sometimes a post here on The Niche (named after the stem cell niche) sparks a debate between expert stem cell researchers and often that gives much more depth to a topic. Such was the case with my post this week on where things stand with stem cell therapy for heart disease. It led to a
Weekly reads: Melton leaves Harvard, Fuji, BBC blunder, stem cell niche, more Read More »
The big news of the week was a $3.6 million settlement by a stem cell clinic, StemGenex, and one of its doctors in a class-action suit. I covered this StemGenex settlement and so did Michael Hiltzik of the LA Times and Paul Schloesser at Endpoints. I’d say this was good news for the stem cell field
Stem cell weekly reads: Jamie Thomson, Lamin B1, CRISPR Read More »
The idea of stem cells outright curing diseases is exciting and has powerful appeal, but media need to be careful about using the word cure in headlines and articles as we saw this week related to a possible HIV Cure. HIV cure via stem cells and chemo? The big news of the week was that
Weekly reads: possible rare HIV cure, stem cell chicken, FDA commish Read More »
When we hear the word senile we might think stereotypically of an older person who has cognitive impairment, but some argue that senility can apply to cells too as they age and that such cells can be targeted by drugs called senolytics. Unfortunately, the supplements industry has picked up on this idea to sell iffy
Recommended reads: senolytics, cow iPS cells, big CIRM royalty Read More »